Phase I/Ib Study of TBI-2001 for Patients With Relapsed or Refractory CD19+ B-cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Latest Information Update: 14 Aug 2024
At a glance
- Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; TBI 2001 (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- 15 Mar 2024 Planned End Date changed from 30 Nov 2025 to 30 May 2026.
- 15 Mar 2024 Planned primary completion date changed from 30 Nov 2024 to 30 Mar 2025.
- 04 Aug 2023 New trial record